| SC 13G/A | 2024-03-26 | Cystic Fibrosis Foundation | BiomX Inc. | 9,330,580 | 15.6% | EDGAR |
| SC 13G | 2024-03-25 | AMR Action Fund, L.P. | BiomX Inc. | 3,054,870 | 5.5% | EDGAR |
| SC 13D | 2024-03-22 | Flynn James E | BiomX Inc. | 3,055,049 | 5.5% | EDGAR |
| SC 13D/A | 2024-03-19 | OrbiMed Israel BioFund GP Limited Partnership | BiomX Inc. | 12,577,821 | 19.9% | EDGAR |
| SC 13D/A | 2024-03-08 | OrbiMed Israel BioFund GP Limited Partnership | BiomX Inc. | 4,601,808 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-13 | MMCAP International Inc. SPC | BiomX Inc. | 1,527,994 | 3.2% | EDGAR |
| SC 13G/A | 2024-02-02 | JOHNSON & JOHNSON | BiomX Inc. | 2,113,402 | 4.6% | EDGAR |
| SC 13G/A | 2024-01-30 | Cystic Fibrosis Foundation | BiomX Inc. | 4,552,315 | 9.9% | EDGAR |
| SC 13G | 2023-09-29 | Centaurus Investments Ltd | BiomX Inc. | 2,839,714 | 6.2% | EDGAR |
| SC 13G | 2023-06-23 | Burbank John Howard III | BiomX Inc. | 4,598,189 | 10.0% | EDGAR |
| SC 13D/A | 2023-05-08 | OrbiMed Israel BioFund GP Limited Partnership | BiomX Inc. | 4,553,489 | 9.9% | EDGAR |
| SC 13D/A | 2023-03-17 | OrbiMed Israel BioFund GP Limited Partnership | BiomX Inc. | 3,536,489 | 10.5% | EDGAR |
| SC 13G | 2023-03-08 | Cystic Fibrosis Foundation | BiomX Inc. | 2,750,988 | 8.1% | EDGAR |
| SC 13G/A | 2023-02-14 | MMCAP International Inc. SPC | BiomX Inc. | 2,222,881 | 7.1% | EDGAR |
| SC 13G/A | 2023-02-13 | Ugwumba Chidozie | BiomX Inc. | 922,800 | 3.1% | EDGAR |
| SC 13G/A | 2022-11-14 | Ugwumba Chidozie | BiomX Inc. | 2,997,025 | 10.0% | EDGAR |
| SC 13G/A | 2022-08-05 | TAKEDA PHARMACEUTICAL CO LTD | BiomX Inc. | 1,478,286 | 5.0% | EDGAR |
| SC 13G | 2022-02-14 | Ugwumba Chidozie | BiomX Inc. | 5,512,846 | 19.3% | EDGAR |
| SC 13G | 2022-02-14 | Walton Thomas Layton | BiomX Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-04 | MMCAP International Inc. SPC | BiomX Inc. | 2,115,639 | 7.5% | EDGAR |